The US Food and Drug Administration (FDA) granted accelerated approval to neladalkib (Nelkarmi) on November 17, 2026, for adults with previously treated, locally advanced or metastatic anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC). The decision introduces another targeted treatment option for patients whose cancer has progressed after specified prior ALK-directed therapies.
The approval, announced by GSK following its acquisition of Nuvalent, is based on results from the Phase I/II ALKOVE-1 trial, which demonstrated tumor responses in patients previously treated with ALK tyrosine kinase inhibitors (TKIs). Among the two populations supporting the approval, confirmed overall response rates reached 49% and 32%, respectively, with approximately half of responding patients in each group maintaining their responses for at least 12 months.
Neladalkib was developed to address several persistent challenges in ALK-positive lung cancer, including acquired resistance to existing therapies and the development of brain metastases. Its approval comes ahead of the FDA’s original target action date of November 27, 2026, following previous Breakthrough Therapy and Orphan Drug designations.
Who Is Eligible for Neladalkib?
The FDA approval covers adult patients with unresectable locally advanced or metastatic ALK-positive NSCLC who have previously received either:
- One prior ALK TKI, specifically alectinib, in the advanced disease setting.
- Two or more prior ALK TKIs and platinum-based chemotherapy.
This distinction is important because the approval is not a broad authorization for all patients previously treated with ALK inhibitors. It applies to the specific treatment histories evaluated in the supporting clinical trial.
ALK rearrangements define a molecularly distinct subgroup of NSCLC in which targeted treatments have substantially changed disease management. However, even when initial responses are prolonged, resistance can eventually emerge, creating a need for additional therapies that remain active after earlier ALK inhibitors.
ALKOVE-1 Trial Demonstrates Responses in Previously Treated Patients
The approval was supported by the global, multicenter, open-label, single-arm Phase I/II ALKOVE-1 trial (NCT05384626), which investigated neladalkib in patients with advanced ALK-positive NSCLC and other ALK-positive solid tumors.
The primary efficacy analysis supporting FDA approval included 222 patients with previously treated ALK-positive NSCLC. The major efficacy endpoints were confirmed overall response rate (ORR) and duration of response (DOR), assessed by blinded independent central review according to RECIST v1.1.
In patients who had previously received alectinib as their only ALK inhibitor, the confirmed ORR was 49% (33 of 67 patients; 95% CI, 37–62%). Among responders, 76% maintained their responses for at least six months, while 52% maintained responses for at least 12 months.
Among patients previously treated with two or more ALK inhibitors and platinum-based chemotherapy, the confirmed ORR was 32% (50 of 155 patients; 95% CI, 24–40%). In this more heavily pretreated population, 69% of responders had responses lasting at least six months, and 51% maintained responses for at least 12 months.
These findings indicate antitumor activity in both previously treated populations, including patients exposed to multiple prior therapies. However, ALKOVE-1 was a single-arm study without a randomized comparator, and the approval was based on response rate and duration rather than demonstrated improvements in overall survival.
Intracranial Activity in Patients With Brain Metastases
Brain metastases are an important clinical challenge in ALK-positive NSCLC, particularly as patients live longer and receive multiple successive treatments. Neladalkib was designed to cross the blood-brain barrier and retain activity against a range of ALK resistance mutations.
The ALKOVE-1 trial also reported intracranial responses among patients with measurable central nervous system metastases at baseline.
In patients previously treated with alectinib alone, the intracranial ORR was 55% (11 of 20 patients), including complete intracranial responses in 25%.
Among patients who had received two or more ALK inhibitors and platinum-based chemotherapy, the intracranial ORR was 26% (14 of 53 patients), with complete intracranial responses reported in 11%.
These findings suggest that neladalkib can produce intracranial tumor responses in selected previously treated patients, including those with more extensive prior treatment exposure. The relatively small intracranial efficacy populations and single-arm trial design should be considered when interpreting these results.
Safety Profile and Recommended Dosing
Neladalkib is administered orally at a recommended dose of 150 mg once daily, with or without food, until disease progression or unacceptable toxicity.
Safety findings were reported from a pooled population of 700 patients treated in ALKOVE-1. The most frequently reported adverse reactions included hepatotoxicity (56%), musculoskeletal pain (33%), constipation (28%), dysgeusia (24%), peripheral neuropathy (23%), edema (21%), and fatigue (21%).
Serious adverse reactions occurred in 30% of the 656 patients with ALK-positive NSCLC included in the serious adverse reaction analysis, while permanent treatment discontinuation due to adverse reactions occurred in 5% of patients. Hepatotoxicity was the most frequent adverse reaction leading to permanent discontinuation.
The prescribing information includes warnings for hepatotoxicity, renal toxicity, ocular toxicity, creatine phosphokinase elevation, and embryo-fetal toxicity. Regular monitoring of liver function, kidney function, and creatine phosphokinase levels is recommended, particularly during the initial months of treatment.
Why This Approval Matters for ALK Positive Lung Cancer
The treatment landscape for ALK-positive NSCLC has changed considerably over the past decade. Successive generations of ALK inhibitors have enabled many patients to achieve prolonged disease control, shifting attention toward treatment sequencing, resistance mechanisms, central nervous system protection, and long-term tolerability.
Lorlatinib has become an important first-line treatment option, while alectinib, brigatinib, and ensartinib remain relevant alternatives. Nevertheless, disease progression remains a concern, and the optimal treatment strategy after multiple ALK inhibitors is not always clear.
Neladalkib adds another FDA-approved option for patients meeting its specific eligibility criteria, although its relative effectiveness against existing later-line therapies remains to be established.
The importance of having additional treatment options was also emphasized by Kirk Smith, President of ALK Positive, who described the experience of progression after a previously effective therapy:
“One of the hardest moments is learning that a treatment that had been working is no longer controlling the disease.”
For patients who may require several successive therapies over many years, maintaining disease control while preserving quality of life remains an important treatment goal.
What’s Next for Neladalkib?
Beyond its newly approved indication, neladalkib is being evaluated in the ongoing Phase III ALKAZAR trial (NCT06765109), which compares neladalkib with alectinib as first-line treatment for patients with advanced ALK-positive NSCLC who have not previously received an ALK inhibitor.
This randomized study is designed to evaluate whether neladalkib can improve progression-free survival compared with alectinib. Its findings could help clarify the drug’s potential role earlier in the treatment pathway, beyond the previously treated population covered by the current approval.
The November approval also represents GSK’s second new lung cancer medicine approved in the United States in 2026. In July, the FDA approved zidesamtinib for previously treated ROS1-positive advanced NSCLC. Both medicines originated from Nuvalent, which GSK acquired in 2026.
For now, neladalkib’s approval remains accelerated and is based on tumor response rate and duration of response. Continued approval may depend on verification of clinical benefit through confirmatory evidence.
The decision expands treatment options for a defined group of patients with advanced ALK-positive NSCLC while leaving important questions about optimal sequencing, comparative effectiveness, and long-term outcomes for future clinical research.
Read further on OncoDaily: FDA Approves Giredestrant Plus Everolimus for ER-Positive Advanced Breast Cancer With ESR1 Mutations

